OptiLight Info Kit
A Bright Solution for Dry Eyes
Brochures, Clinical Studies, Testimonial Video, and more…
Download your Info Kit Now!
Meet the First and Only IPL FDA Approved for Dry Eye Management
EVERY ELEMENT DESIGNED FOR A PRECISE,
COMFORTABLE DRY EYE PROCEDURE
Patented OPT® Handpiece
Treat the delicate facial contours of each individual patient. The patented OPT® handpiece is easily customized to fit every curve and outline.
Ergonomic IPL Handpiece
Treat wider areas safely and comfortably using the IPL handpiece with patented SapphireCoolTM technology to effectively break dry eye's vicious cycle of inflammation.
Personalized Experience for Maximum Safety and Comfort
Experience optimal energy control at the tip of your OptiLight, for targeted, precise, hygienic and controlled treatment, especially for delicate areas.
Proven Settings and Protocols
Utilize embedded settings based on Lumenis’ clinically validated treatment protocols for safe and effective treatment.
Transforming the use of light with OPT® technology
With the Patented Optimal Pulse Technology (OPT®) you can deliver targeted, precise and controlled treatment. The energy you set is the energy you get -optimal energy with a no-spike consistency.
Seamless Workflow
Import last session’s data for a quick setup, and generate automatic treatment reports for a streamlined workflow and enhanced efficiency.
Indication for Use:
In EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). This indication is intended for Fitzpatrick skin types I-V.
In US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses.
The indications are only relevant where they were approved by the Regulatory Authorities.
Treatment with OptiLight is contraindicated for patients with the following conditions in the treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; History of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks.
The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks.